Time to Viral Re-suppression and Its Predictors among Adults on Second-Line Antiretroviral Therapy in South Wollo Zone Public Hospitals: Stratified Cox Model

References

• World Health Organization. Global Health Sector Strategy on HIV 2016–2021. World Health Organization; 2016.
   Google Scholar
• UNAIDS. An Ambitious Treatment Target to Help End the AIDS Epidemic. UNAIDS; 2014.
   Google Scholar
• UNAIDS. United Nations programme on HIV/AIDS. In: The Gap Report. Geneva: UNAIDS; 2014:1–334.
   Google Scholar
• World Health Organization. Technical Report Aids Medicines and Diagnostics Service. World Health Organization; 2020.
   Google Scholar
• Jensen DM. Monitoring and switching of first-line antiretroviral therapy in sub-Saharan Africa: collaborative analysis of adult treatment cohorts. Physiol Behav. 2018;176(1):1570–1573.
   Google Scholar
• Assefa Y, Gilks CF, Lynen L, et al. International journal of infectious diseases performance of the antiretroviral treatment program in Ethiopia, 2005–2015: strengths and weaknesses toward ending AIDS. Int J Infect Dis. 2017;60:70–76. doi:10.1016/j.ijid.2017.05.012
   PubMed Web of Science ®Google Scholar
• Avert. “Alarming” rates of second-line HIV treatment failure in sub-Saharan Africa; 2019.
   Google Scholar
• Phillips A, Shroufi A, Vojnov L, et al. Sustainable HIV treatment in Africa through viral-load-informed differentiated care. Nature. 2015;528(7580):S68–76. doi:10.1038/nature16046
   PubMed Web of Science ®Google Scholar
• Suppression VL. Reaching the third 95: viral load suppression among key population individuals living with HIV. 2013.
   Google Scholar
• UNAIDS. The need for routine viral load testing. Available from: http://www.unaids.org/sites/default/files/media_asset/JC2845_en.pdf. Accessed June 12, 2023.
   Google Scholar
• Centers for Disease Control and Prevention. Evidence of HIV treatment and viral suppression in preventing the sexual transmission of HIV. Dep Heal Hum Serv. 2018;4:15.
   Google Scholar
• Chkhartishvili N, Sharvadze L, Dvali N, et al. Virologic outcomes of second-line antiretroviral therapy in Eastern European country of Georgia. AIDS Res Ther. 2014;11(1):1–6. doi:10.1186/1742-6405-11-18
   PubMedGoogle Scholar
• Murphy RA, Sunpath H, Castilla C, et al. Second-line antiretroviral therapy: long-term outcomes in South Africa. J Acquir Immune Defic Syndr. 2012;61(2):158–163. doi:10.1097/QAI.0b013e3182615ad1
   PubMed Web of Science ®Google Scholar
• Huang X, Xu L, Sun L, et al. Six-year immunologic recovery and virological suppression of HIV patients on LPV/R-based second-line antiretroviral treatment: a multi-center real-world cohort study in China. Front Pharmacol. 2019;10:1–8. doi:10.3389/fphar.2019.01455
   PubMed Web of Science ®Google Scholar
• Shearer K, Evans D, Moyo F, et al. Treatment outcomes of over 1000 patients on second-line, protease inhibitor-based antiretroviral therapy from four public-sector HIV treatment facilities across Johannesburg, South Africa. Trop Med Int Heal. 2017;22(2):221–231. doi:10.1111/tmi.12804
   PubMed Web of Science ®Google Scholar
• Chakravarty J, Sundar S, Chourasia A, et al. Outcome of patients on second line antiretroviral therapy under programmatic condition in India. BMC Infect Dis. 2015;15(1). doi:10.1186/s12879-015-1270-8
   PubMedGoogle Scholar
• Johnston V, Fielding K, Charalambous S, et al. Second-line antiretroviral therapy in a workplace and community-based treatment programme in South Africa: determinants of virological outcome. PLoS One. 2012;7(5):e36997. doi:10.1371/journal.pone.0036997
   PubMed Web of Science ®Google Scholar
• Chen J, Zhang M, Shang M, Yang W, Wang Z, Shang H. Research on the treatment effects and drug resistances of long-term second-line antiretroviral therapy among HIV-infected patients from Henan Province in China. BMC Infect Dis. 2018;18:1–12.
   PubMed Web of Science ®Google Scholar
• Fox MP, Ive P, Long L, Maskew M, Sanne I. High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010;53(4):500–506. doi:10.1097/QAI.0b013e3181bcdac1
   PubMed Web of Science ®Google Scholar
• Desai M, Dikshit R, Patel D, Shah A. Early outcome of second line antiretroviral therapy in treatment-experienced human immunodeficiency virus positive patients. Perspect Clin Res. 2013;4(4):215. doi:10.4103/2229-3485.120170
   PubMedGoogle Scholar
• Report F. Ethiopia population-based HIV impact assessment; 2020.
   Google Scholar
• Pepfar. Ethiopia country operational plan COP2020/FY2021 strategic direction summary; 2020.
   Google Scholar
• Wedajo S, Degu G, Deribew A, Ambaw F. Rate of viral re-suppression and retention to care among plhiv on second-line antiretroviral therapy at Dessie comprehensive specialized hospital, northeast Ethiopia: a retrospective cohort study. HIV/AIDS - Res Palliat Care. 2021;13:877–887. doi:10.2147/HIV.S323445
   Web of Science ®Google Scholar
• Care P. Epidemiology of HIV infection in the Amhara Region of Ethiopia, 2015 to 2018 surveillance data analysis; 2020.
   Google Scholar
• Departement South Wollo Zonal Health. south wollo zone health facility five month ART utilization report; 2013.
   Google Scholar
• Médecins Sans Frontières. Making viral load routine: successes and challenges in the implementation of routine HIV viral load monitoring. UNITAID Rep. 2016;2016:1–35.
   Google Scholar
• Federal Ministry of Health of Ethiopia. National comprehensive HIV prevention, care, and treatment training for pharmacy professionals participant manual; 2018.
   Google Scholar
• Maina EK, Mureithi H, Adan AA, Muriuki J, Lwembe RM, Bukusi EA. Incidences and factors associated with viral suppression or rebound among HIV patients on combination antiretroviral therapy from three counties in Kenya. Int J Infect Dis. 2020;97:151–158. doi:10.1016/j.ijid.2020.05.097
   PubMed Web of Science ®Google Scholar
• Finci I, Flores A, Gutierrez Zamudio AG, et al. Outcomes of patients on second- and third-line ART enrolled in ART adherence clubs in Maputo, Mozambique. Trop Med Int Heal. 2020;25(12):1496–1502. doi:10.1111/tmi.13490
   PubMed Web of Science ®Google Scholar
• Diress G, Dagne S, Alemnew B, Adane S, Addisu A. Viral load suppression after enhanced adherence counseling and its predictors among high viral load HIV seropositive people in North Wollo Zone public hospitals, Northeast Ethiopia, 2019: retrospective cohort study. AIDS Res Treat. 2020;2020:154.
   Web of Science ®Google Scholar
• Desta AA, Woldearegay TW, Futwi N, et al. HIV virological non-suppression and factors associated with non-suppression among adolescents and adults on antiretroviral therapy in northern Ethiopia: a retrospective study. BMC Infect Dis. 2020;20(1):1–10. doi:10.1186/s12879-019-4732-6
   Web of Science ®Google Scholar
• Bezabhe WM, Chalmers L, Bereznicki LR, Peterson GM, Bimirew MA, Kassie DM. Barriers and facilitators of adherence to antiretroviral drug therapy and retention in care among adult HIV-positive patients: a qualitative study from Ethiopia Article ID e97353. PLoS One. 2014;9(5).
   PubMed Web of Science ®Google Scholar
• Patel D, Cortina-Borja M, Thorne C, et al. Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis. 2007;44(12):1647–1656.
   PubMed Web of Science ®Google Scholar
• Li X, Ding H, Geng W, et al. Predictive effects of body mass index on immune reconstitution among HIV-infected HAART users in China. BMC Infect Dis. 2019;19(1):1–9. doi:10.1186/s12879-018-3567-x
   PubMed Web of Science ®Google Scholar
• Ferradini L, Ouk V, Segeral O, et al. High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. J Int AIDS Soc. 2011;14(1):14. doi:10.1186/1758-2652-14-14
   PubMedGoogle Scholar
• Ndashimye E, Arts EJ. The urgent need for more potent antiretroviral therapy in low-income countries to achieve UNAIDS 90-90-90 and complete eradication of AIDS by 2030. Infect Dis Poverty. 2020;1(2019):1–8.
   Google Scholar
• Huang Y, Huang X, Luo Y, et al. Assessing the efficacy of lopinavir/ritonavir-based preferred and alternative second-line regimens in HIV-infected patients: a meta-analysis of key evidence to support WHO recommendations. Front Pharmacol. 2018;9:1–12. doi:10.3389/fphar.2018.00890
   PubMed Web of Science ®Google Scholar